Dr. Chinna Naik Banoth
Consultant, Nuclear Medicine
Qualifications
- DNB Nuclear Medicine - RMC, BARC Hospital, Mumbai.
- MBBS - Osmania Medical College, Koti, Hyderabad.
Experience
- Consultant & HOD–Nuclear Medicine/PET-CT at OMEGA Hospitals, Hyderabad [November 2020 – Dec 2024]
- Nuclear Medicine Physician at KIMS Hospital, Secunderabad [December 2017 – November 2020]
- Consultant–Nuclear Medicine at Vijaya Diagnostic Centre, Hyderabad [September 2016 – December 2017]
Field of Expertise
- Onco Imaging.
- Hybrid Imaging.
- Nuclear Endocrinology.
- Targeted Radionuclide Therapy.
- Internal Radiation Dosimetry.
Research & Publications
- Clinical Utility of 177 Lu-DOTATATE PRRT - Focus on metastatic medullary carcinoma of the thyroid. Published in Head Neck (2020).
- 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy - Study on renal parameters and treatment feasibility. Published in World J Nucl Med (2018).
- Synchronous Malignancies - Thyroglossal duct cyst and thyroid gland. Published in Natl Med J India (2017).
- Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumor - Associated with multiple endocrine neoplasia type 1 and Cushing's syndrome. Published in World J Nucl Med (2017).
- Mucoepidermoid Parotid Gland Tumor - Identified during follow-up radioiodine scan for differentiated papillary thyroid cancer. Published in J Nucl Med Technol (2017).
Certifications & Memberships
Nanakramguda
Qualifications
- DNB Nuclear Medicine - RMC, BARC Hospital, Mumbai.
- MBBS - Osmania Medical College, Koti, Hyderabad.
Experience
- Consultant & HOD–Nuclear Medicine/PET-CT at OMEGA Hospitals, Hyderabad [November 2020 – Dec 2024]
- Nuclear Medicine Physician at KIMS Hospital, Secunderabad [December 2017 – November 2020]
- Consultant–Nuclear Medicine at Vijaya Diagnostic Centre, Hyderabad [September 2016 – December 2017]
Field of Expertise
- Onco Imaging.
- Hybrid Imaging.
- Nuclear Endocrinology.
- Targeted Radionuclide Therapy.
- Internal Radiation Dosimetry.
Research & Publications
- Clinical Utility of 177 Lu-DOTATATE PRRT - Focus on metastatic medullary carcinoma of the thyroid. Published in Head Neck (2020).
- 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy - Study on renal parameters and treatment feasibility. Published in World J Nucl Med (2018).
- Synchronous Malignancies - Thyroglossal duct cyst and thyroid gland. Published in Natl Med J India (2017).
- Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumor - Associated with multiple endocrine neoplasia type 1 and Cushing's syndrome. Published in World J Nucl Med (2017).
- Mucoepidermoid Parotid Gland Tumor - Identified during follow-up radioiodine scan for differentiated papillary thyroid cancer. Published in J Nucl Med Technol (2017).
